ORION Biotech Catalyst Calendar
Menu

Registry study list as of Sep 26, 2026. For current SEC-sourced timing by company, see Companies A–Z.

FIND / RETAIN / COMPARE

One study.
A starting point you keep.

Last updated (page presentation): . Page presentation only; original policy, publication and source-review dates remain unchanged. This is not a new data or service-availability check.

50 companies · 50 selected studies as of on the daily collection schedule. Search by ticker, company, drug, disease or NCT ID.

One selected study per company. Open a company to read its available sources, or keep a study in your watchlist.

50 studies shown as of

RCKT · SELECTED REGISTRY STUDY

ROCKET PHARMACEUTICALS, INC.

RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) · NCT07137338

Dilated Cardiomyopathy (DCM)

Identity verified 2026-09-26. Latest collection availability appears in your study desk.

Company evidence →Original registry ↗Keep this starting point
Coverage, dates & collection method

Reviewed historical examples: 10 companies, 10 milestones and 24 source records from 2022–2025. Recorded by ORION on September 26, 2026. This is a selected evidence set, not a complete company history or continuous monitoring. Later company disclosures may change the current picture. Publication dates are not ORION detection dates.

This registry collection is separate from the 10 company histories with 24 historical announcement records. It is not whole-company surveillance or 50 validated AI analysis reports. Reviewed changes appear when found; missing data stays unavailable.

Primary completion dates are registry dates, not company promises to publish results. Source collection and human review can be delayed.

Each history connects the same company, medicine and development milestone. A registry date, a different indication or a headline mentioning the same drug is not sufficient evidence of the same milestone. Trial identifiers appear only where the sources establish the link.

“Outcome reported” means the company disclosed a result or action, not that ORION independently verified efficacy or approval. An elapsed target window alone never becomes a broken promise. An unclear window or missing follow-up remains “Not yet verified.” “Mid-year” and similar wording are preserved without inventing a precise date.

Publication dates belong to original documents. “ORION first recorded” is when this historical entry entered our catalog; it is not a claim that we discovered the information before the market. Effective dates can be unavailable. Historic entries can be added later.

Records are retained when corrected. A correction identifies the older entry and the reason. A technical fingerprint can detect changes to a published dataset; it does not prove that a company statement is true, that the collection is complete, or that an independent party timestamped it.

Public corrections log · Read the current catalog manifest · Research methodology. No investment scores, rankings, recommendations, price targets or forecasts.

This is a follow-up research question, not an answered claim or forecast. Later disclosures may not be included in this release.